BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) saw a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 1,110,000 shares, a drop of 25.0% from the March 31st total of 1,480,000 shares. Based on an average trading volume of 2,540,000 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BIVI. Jump Financial LLC purchased a new stake in BioVie in the 3rd quarter valued at approximately $34,000. Summit Trail Advisors LLC purchased a new stake in shares of BioVie in the third quarter valued at approximately $34,000. Finally, Crescent Grove Advisors LLC purchased a new stake in shares of BioVie in the third quarter valued at approximately $38,000. 4.59% of the stock is currently owned by institutional investors and hedge funds.

BioVie Stock Performance

Shares of BIVI stock remained flat at $0.48 during midday trading on Friday. The company’s stock had a trading volume of 316,995 shares, compared to its average volume of 800,879. The firm has a market capitalization of $19.35 million, a PE ratio of -0.41 and a beta of 0.79. The stock has a 50-day simple moving average of $0.72 and a 200 day simple moving average of $1.71. BioVie has a one year low of $0.45 and a one year high of $8.69.

BioVie (NASDAQ:BIVI) last announced its quarterly earnings data on Monday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.10. Analysts forecast that BioVie will post -1 EPS for the current fiscal year.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.